Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2015 February;63(1) > Minerva Cardioangiologica 2015 February;63(1):21-9

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Cite this article as

 

REVIEWS   

Minerva Cardioangiologica 2015 February;63(1):21-9

Copyright © 2015 EDIZIONI MINERVA MEDICA

language: English

TIDES-ACS Trial: comparison of titanium-nitride-oxide coated bio-active-stent to the drug (everolimus)-eluting stent in acute coronary syndrome. Study design and objectives

Colkesen E. B. 1, Eefting F. D. 1, Rensing B. J. 1, Suttorp M. J. 1, Ten Berg J. M. 1, Karjalainen P. P. 2, Van Der Heyden J. A. 1

1 Department of Cardiology, St. Antonius Hospital, Nieuwegein the Netherlands; 2 Department of Cardiology, Heart Center, Satakunta Central hospital, Pori, Finland


PDF


Drug-eluting stents (DES), delivering antiproliferative drugs from a durable polymer, have shown to reduce in-stent restenosis after percutaneous coronary intervention (PCI) compared to bare-metal stents (BMS). However, they have been associated with a hypersensitivity reaction, delayed healing, and incomplete endothelialization, which may contribute to an increased risk of late stent thrombosis. Consequently, a prolonged duration of dual antiplatelet therapy (DAPT) is needed, with an increased risk of bleeding complication. A number of stent technologies are being developed in an attempt to modify late thrombotic events and DAPT duration. The Optimax™ stent is such a novel, next generation bioactive stent (BAS), in which a thicker layer of titanium-nitride-oxide coating is inserted over the stent struts. The rationale of this is to obtain more efficient and rapid vascular healing at the site of the stent implantation. The aim of TIDES-ACS Trial is to compare clinical outcome in patients presenting with ACS, treated with PCI using Optimax-BAS versus Synergy™-EES. Second objective is to explore whether the Optimax™-BAS use is superior compared with Synergy™-EES use with respect of hard end points (cardiac death, myocardial infarction [MI] and major bleeding). A prospective, randomized, multicenter trial (ClinicalTrials.gov Identifier: NCT02049229), will be conducted in interventional centres in Finland (six centres), France (five centres) and Holland (two centres), including a total of 1800 patients.

top of page